Cadrenal Therapeutics (CVKD) Non-Current Assets (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Non-Current Assets of $6786.0 for Q1 2026, down 7.56% sequentially from $7341.0 in Q4 2025, and down 19.88% YoY from $8470.0 in Q1 2025.
Cadrenal Therapeutics (CVKD) Non-Current Assets (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $6786.0 in Q1 2026.
- Quarterly Non-Current Assets fell 19.88% year-over-year to $6786.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28467.0 (down 28.25% YoY) and the FY2025 annual result came in at $7341.0, down 31.62% from the prior year.
- Non-Current Assets eased to $6786.0 in Q1 2026 per CVKD's latest filing, from $7341.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $50578.0 in Q4 2022 and troughed at $6444.0 in Q2 2025.
- A 5-year average of $20175.5 and a median of $12201.5 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 79.74% in 2024, then advanced 16.07% in 2025.
- Over 5 years, Non-Current Assets stood at $50578.0 in 2022, then tumbled by 46.46% to $27077.0 in 2023, then sank by 60.35% to $10736.0 in 2024, then sank by 31.62% to $7341.0 in 2025, then fell by 7.56% to $6786.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6786.0, $7341.0, and $7896.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Cadrenal Therapeutics | 4.66 Mn | 2.26 Mn | - | 4,842.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,842.00 |
| Mar 31, 2026 | 6,786.00 |
| Dec 31, 2025 | 7,341.00 |
| Sep 30, 2025 | 7,896.00 |
| Jun 30, 2025 | 6,444.00 |
| Mar 31, 2025 | 8,470.00 |
| Dec 31, 2024 | 10,736.00 |
| Sep 30, 2024 | 6,803.00 |
| Jun 30, 2024 | 13,667.00 |
| Mar 31, 2024 | 20,402.00 |
| Dec 31, 2023 | 27,077.00 |
| Sep 30, 2023 | 33,571.00 |
| Jun 30, 2023 | 39,892.00 |
| Mar 31, 2023 | 42,794.00 |
| Dec 31, 2022 | 50,578.00 |